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Background. Differences in healthcare and cancer treatment for cancer survivors in the United States (US) have not been routinely
examined in nationally representative samples or studied before and after important Institute ofMedicine (IOM) recommendations
calling for higher quality care provision and attention to comprehensive cancer care for cancer survivors. Methods. To assess
differences between survivor characteristics in 1992 and 2010, we conducted descriptive analyses of 1992 and 2010 National Health
Interview Survey (NHIS) data. Our study sample consisted of 1018 self-reported cancer survivors from the 1992 NHIS and 1718
self-reported cancer survivors from the 2010 NHIS who completed the Cancer Control (CCS) and Cancer Epidemiology (CES)
Supplements.Results.The prevalence of reported survivors increased from 1992 to 2010 (4.2% versus 6.3%). From 1992 to 2010, there
was an increase in long-term cancer survivors and a drop in multiple malignancies, and surgery remained the most widely used
treatment. Significantly fewer survivors (<10 years after diagnosis) were denied insurance coverage. Survivors continue to report low
participation in counseling or support groups.Conclusions. As the prevalence of cancer survivors continues to grow,monitoring dif-
ferences in survivor characteristics can be useful in evaluating the effects of policy recommendations and the quality of clinical care.
1. Introduction
Advances in cancer detection, diagnosis, and treatment,
along with the aging of the United States (US) population,
have resulted in a large and growing number of cancer sur-
vivors. Recent estimates indicate that there are nearly 14 mil-
lion cancer survivors in the US, more than the over 7 million
cancer survivors reported in 1992 [1–3]. Although research
examining sociodemographic and healthcare characteristics
of nationally representative samples of cancer survivors has
been conducted [4, 5], differences in these characteristics over
time have rarely been examined in population-based studies.
In 1992, the National Health Interview Survey (NHIS)
examined characteristics of cancer survivors as part of its
Cancer Control Supplement for the first time. Hewitt and col-
leagues published findings from the 1992NHIS about numer-
ous self-reported cancer survivor characteristics, including
demographic information, cancer type, frequency of second
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opinion concerning type of cancer treatment, counseling
and support group services, patient education, contact with
cancer organizations, participation in clinical trials, health
and life insurance coverage, and concerns with employment
[4]. Findings showed that cancer survivors were largely
females, over the age of 65 years, and were most often
diagnosed with female gynecologic, breast, colorectal, and
prostate/male reproductive cancers [4]. Additionally, 44%
of cancer survivors reported not receiving a second opin-
ion about their cancer treatment and very few survivors
reported participating in clinical trials or receiving coun-
seling/supportive services [4]. Lastly, one in nine survivors
reported being denied health or life insurance coverage due
to their cancer diagnosis and one in five survivors reported
employment concerns [4]. As a result of this and an emerging
body of studies [6, 7] illustrating gaps in the followup
care of and health disparities experienced by survivors, the
Institute of Medicine (IOM) published a report highlighting
the importance of tracking and providing quality care and
support for survivors’ medical, psychosocial, employment,
and insurance coverage needs, while also emphasizing the
need for additional research and clinical trials [8, 9]. In 2008,
the IOM released an additional report, “Cancer Care for the
Whole Patient”, describing the psychosocial needs of can-
cer survivors including information and emotional support
about diagnosis and treatment, resources for transportation
and financial concerns, and issues related to disruptions
in employment or academic progression, while providing
recommendations about supportive and psychosocial health
services to address these concerns [9].
In 2010, NHIS again collected data on cancer survivors
in order to examine demographic, diagnostic, treatment, and
other healthcare characteristics of this growing population.
In response to IOM and other reports advising tracking
quality care and characteristic of survivors overtime, our
study compares reported demographics, cancer diagnosis
and treatment, psychosocial care, research participation, and
insurance coverage between cancer survivors who responded
to the 1992NHIS and those who responded to the 2010NHIS.
2. Methods
2.1. Data Sources. The NHIS is a population-based, cross-
sectional household survey conducted annually by the Cen-
ters for Disease Control and Prevention (CDC), National
Center for Health Statistics (NCHS), and administered by
the US Census Bureau. Since 1957, the NHIS has collected
data on civilian, noninstitutionalizedUS adults (aged 18 years
or older) in order to examine healthcare status, access, and
progress made towards improving health outcomes in the
United States. Beginning in 1987, the NHIS began collecting
data on cancer control and epidemiology. Over time, the
NHIS has included various survey components. The 1992
NHIS survey consisted of a two-part questionnaire. The first
part, or Core Section, consisted of a set of general health and
demographic questions, while the second part, or supplement
sections, contained more specific questions about health
topics of interest. The 1992 NHIS survey incorporated two
cancer supplements: the Cancer Control Supplement (CCS)
and the Cancer Epidemiology Supplement (CES), both of
which included questions on cancer survivorship (Cancer
Survivorship Section).
These questions were administered, using a split survey
design, to one randomly selected adult aged 18 years and older
in each of the 49,401 households sampled.The administration
of the Cancer Survivorship Section on each supplement
was suspended during the third quarter of the field admin-
istration due to budgetary constraints, yielding an overall
response rate of 87% for the CCS and an 86% response rate
for the CES [4]. Starting in 2000, cancer control data (which
primarily focus on risk factors and screening behavior) have
been collected in one CCS every five years. Additionally,
all NHIS surveys administered after 1997 were revised to
include additional questions on insurance coverage, health-
care access, and health behaviors. The 2010 administration
of the NHIS was the first survey, since 1992, to include a
more detailed cancer survivorship section within the CCS, an
activity cofunded by the Division of Cancer Prevention and
Control at the CDC and the Division of Cancer Control and
Population Sciences at the National Cancer Institute (NCI).
2.2. Measures. Similar to the 1992 NHIS survey, the 2010
NHIS administration was divided into two parts: the core
and supplement sections. The CCS was fielded on the 2010
NHIS survey; however, several questions were revised since
the 1992 administration. Topic areas covered in the current
analysis and examined in both 1992 and 2010 included demo-
graphic characteristics (age, gender, race/ethnicity, marital
status, education, and employment status and region), cancer
history (number of cancers, cancer type, age at diagnosis and
years since diagnosis, cancer treatments, and participation in
cancer research studies or clinical trials), and healthcare char-
acteristics (impact of cancer on insurance coverage and coun-
seling and supportive group participation related to cancer).
Demographic (age, race/ethnicity, marital status, education,
and employment status) and cancer history (number of can-
cers, cancer type, age at diagnosis, and years since diagnosis)
data were recoded for both 1992 and 2010 surveys. Reported
age at the time of interview and at the time of diagnosis was
recoded to reflect age distributions that are widely used age
parameters for adolescents/young adults, middle adulthood,
and older adulthood (18–29; 30–44; 45–54; 55–64; 65 and
older). While data on racial and ethnic groups other than
Non-Hispanic White, Non-Hispanic Black, and Hispanic
were collected during survey administration, the sample sizes
for these groups were too small for interpretation. Notably,
data concerning cancer type was based on Surveillance Epi-
demiology and End Results (SEER) recodes of definitions for
cancer sites from the International Classification of Diseases
for Oncology, 3rd edition (ICD-O-3) [10]. In the 1992 NHIS
survey, data on healthcare characteristics regarding treatment
type, participation in research studies/clinical trials, impact
of cancer on insurance provision, and involvement and inter-
est in counseling or support groups were only collected for
cancer survivors who were less than 10 years after diagnosis.
Data on healthcare characteristics for respondents to the
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2010 NHIS survey were therefore analyzed separately for
survivors who were less than 10 years after diagnosis and
those 10 years ormore after diagnosis in order to create amore
homogeneous comparison sample.
For the purposes of the current analyses, we included all
respondents who reported ever having been diagnosed with
cancer (cancer survivors). Nonmelanoma skin cancers were
excluded in both samples (1992 and 2010) as they are rarely
invasive and are nearly always treated in a doctor’s office with
no followup. In 1992, there were a total of 24,040 respondents
to the NHIS, of whom 1553 (6.4%) reported ever having
cancer. A total of 1018 (4.2%) respondents were included in
the current analyses, excluding those who reported nonmela-
noma skin cancers, skin cancers of unknown type, and
unknown or ill-defined site (𝑛 = 535). In the 2010 NHIS,
there were a total of 27,157 respondents, 2333 (8.5%) of whom
reported ever having cancer. We excluded 615 respondents
who reported their most recent cancer was for a noneligible
site (nonmelanoma skin or other skin). After exclusions, a
total of 1718 (6.3%) respondents from the 2010 NHIS were
included in the current analyses.
2.3. Statistical Analysis. We used descriptive statistics to
examine differences in reported demographic, cancer history,
and healthcare characteristics among cancer survivors who
were respondents to the 1992 NHIS compared to those
responding to the 2010 NHIS survey. In order to evaluate
whether trends over time were unique to cancer survivors,
additional descriptive analyses examining changes in demo-
graphics between the 1992 and 2010 NHIS surveys among
respondents with no reported history of cancer were also
conducted. In our analyses, we obtained parameter estimates
by maximum likelihood techniques. To account for the com-
plex survey design, SAS (SAS Institute, Cary, NC) version
9.2 and SAS-callable SUDAAN release 10 (Research Triangle
Institute, Research Triangle Park, NC) were used to conduct
all data analyses. Data were suppressed and considered
statistically unreliable when the denominator was based on
<50 sample cases or the Relative Standard Error (RSE) of
the estimate was >30 percent [11]. Where data items were
reported consistently in the 1992 and 2010 NHIS, chi square
tests were used to test for significance differences (𝑃 < 0.05).
Data items that were not reportedly consistently from 1992
to 2010 NHIS were race/ethnicity, marital status, education,
employment status, and cancer type.
3. Results
Theproportion of respondents who reported having a history
of cancer (excluding nonmelanoma and noneligible site can-
cers) increased from 1992 to 2010 (4.2% versus 6.3%). In both
years,most survivorswere females, Non-HispanicWhite, and
not employed or in the labor force (Table 1).
3.1. Changes in Cancer Survivors’ Sociodemographic Charac-
teristics (Table 1). The age distributions of cancer survivors
responding to the NHIS survey in 1992 and 2010 were signifi-
cantly different (𝑃 < 0.001).The proportion of survivors who
reported being 30 to 44 years of age at the time of interview
in 1992 was significantly more than that reported in the 2010
NHIS (16.5% (95% CI = 14.2–19.1) versus 9.4% (95% CI = 8.1–
10.9)) and the proportions of those 55 to 64 and≥65 increased
(17.9% versus 22.6% and 46.9% versus 50.1%, resp.). Similar
changes in age distribution were reported in the general
population of survey respondents with no reported history of
cancer who were 30 to 44 years of age (34.5% versus 26.9%,
resp.), 55 to 64 years of age (10.9% versus 15.5%, resp.), and
≥65 years of age (14.5% versus 17.7%, resp.). The proportion
of male cancer survivors rose and that of female cancer
survivors fell in 2010, compared to 1992 (𝑃 < 0.001). Compar-
atively, no significant changes from 1992 to 2010 in the portion
of males (48.2% versus 45.8%, 𝑃 = 0.32, resp.) and females
(51.8% versus 54.2%, 𝑃 = 0.32, resp.) were found among
respondents with no history of cancer. Fewer survivors
reported being married in 2010 compared to 1992 (44.6%
(95% CI = 42.1–47.2) versus 65% (95% CI = 61.9–68.0)),
while no changes in employment rates and region of resi-
dence were observed. Consistent with cancer survivors, fewer
respondents with no history of cancer also reported being
married in 2010 (44.3%), compared to 1992 (64.6%). The
most pronounced demographic difference between cancer
survivors in 1992 and those in 2010 was the number of years
of education completed. While the largest group of survivors
reported having had no more than a high school education
or GED in both 1992 (65.8% (95% CI = 62.1–69.2)) and 2010
(43.4% (95% CI = 40.9–45.9)), over twice as many survivors
reported having associates, bachelor’s, or graduate degrees in
2010 compared to survivors in 1992 (37.2% (95% CI = 34.5–
40.0) versus 15.9% (95% CI = 13.6–18.7)). This increase of
reported associates, bachelor’s, or graduate degrees from 1992
to 2010 among survivors was also found among respondents
without a history of cancer (20.7% versus 39%).
3.2. Differences in Cancer Diagnostic Characteristics among
Cancer Survivors (Table 2). Thevastmajority of cancer survi-
vors in both 1992 and 2010 reported only having one type of
cancer (86.6% (95% CI = 83.9–88.9) and 89.4% (95% CI =
87.8–90.8), resp.). There was a slight drop in reported rates
of two or more cancer types among survivors from 1992 to
2010 (13.4% (95% CI = 11.1–16.1) versus 10.6% (95% CI =
9.2–12.2), resp.; 𝑃 = 0.05). Breast cancer constituted the
largest group of survivors in both 1992 and 2010. Half asmany
survivors in 2010 reported being diagnosed with other female
gynecological cancers (7.3% (95% CI = 5.9–9.1) versus 14.6%
(95% CI = 12.3–17.3)) compared to respondents in 1992, while
the proportion of prostate cancer survivors increased in 2010.
A drop in the proportion of survivors between the ages
of 30 and 44 years at the time of their cancer diagnosis was
observed from 1992 to 2010; however, an increase in survivors
reporting having a cancer diagnosis between 55 and 64 years
of age was found. Additionally, we found changes in years
since cancer diagnosis, with a larger percentage of survivors
in 2010 reporting that they were 10 to 14 years after diagnosis
or over 20 years after diagnosis (Table 2). Compared to 1992
survivors, significantly fewer survivors in 2010 reported being
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Table 1: Demographic characteristics of cancer survivors, 1992 and 2010 NHIS.
Characteristic 1992 cancer survivors 2010 cancer survivors 𝑃 value
𝑁 % of total (95% confidence interval) 𝑁 % of total (95% confidence interval)
Total 1018 1718
Age at interview (years)
18–29 59 5.9 (4.4–7.8) 58 3.6 (2.7–4.7)
<0.001
30–44 169 16.5 (14.2–19.1) 171 9.4 (8.1–10.9)
45–54 118 12.9 (10.5–15.7) 261 14.3 (12.7–16.1)
55–64 173 17.9 (15.3–20.7) 392 22.6 (20.5–24.8)
65+ 499 46.9 (43.3–50.5) 836 50.1 (47.5–52.7)
Gender
Male 278 31.4 (28.1–35.0) 625 36.6 (34.2–39.1)
<0.001
Female 740 68.6 (64.9–71.9) 1093 63.4 (60.9–65.8)
Race/ethnicity
Non-Hispanic, White 867 88.6 (86.2–90.6) 1239 82.4 (80.6–84.0)
†
Non-Hispanic, Black 84 6.5 (5.1–8.4) 245 9.1 (7.9–10.5)
Hispanic ∗ ∗ 167 5.8 (4.9–6.9)
Other ∗ ∗ 67 2.7 (2.0–3.6)
Marital status
Married 510 65. 0 (61.9–68.0) 766 44.6 (42.1–47.2)
†
Unmarried 505 35.0 (32.0–38.1) 951 55.4 (52.8–57.9)
Education
<High school/high school/GED 673 65.8 (62.1–69.2) 768 43.4 (40.9–45.9)
†Some college 186 18.3 (15.6–21.4) 321 19.4 (17.3–21.8)
Associate degree/college grad/more 156 15.9 (13.6–18.7) 619 37.2 (34.5–40.0)
Employment status
Employed 359 36.6 (33.4–40.0) 576 34.1 (31.8–36.5)
†
Not employed or not in labor force (18+) 659 63.4 (60.0–66.6) 1142 65.9 (63.5–68.2)
Region
Northeast 187 18.7 (15.5–22.4) 290 18.2 (16.0–20.7)
0.817Midwest 279 27.4 (23.7–31.4) 428 25.8 (23.7–28.0)
South 345 34.6 (30.6–38.8) 614 35.0 (32.6–37.5)
West 207 19.4 (16.5–22.6) 386 20.9 (18.7–23.4)
∗Suppressed if the denominator is <50 or the relative standard error (RSE) is >30%.
Differences between 1992 and 2010 data were tested using chi-square tests.
†Statistical tests were not conducted where data were not reported consistently over time.
Subtotals presented do not equal actual totals because respondents with missing data for a particular characteristic are not included in distribution counts for
that characteristic.
1 to 4 years after diagnosis (40.8% (95%CI = 37.4–44.4) versus
29.8% (95% CI = 27.4–32.3)).
3.3. Type of Treatment (Table 3). Differences were observed
regarding types of treatments reported by survivors within
10 years of diagnosis in 1992 compared to survivors in 2010
(Table 3). Over 20% of survivors in 1992 and 2010 reported
receiving a chemotherapy regimen. Radiation therapywas the
second most widely used treatment (after surgery) among
survivors in 1992 and 2010. In 2010, survivors who were 10
years or more after diagnosis reported receiving radiation
treatment less frequently than survivors within 10 years of
diagnosis. The majority of cancer survivors, independent of
NHIS survey administration year or the number of years after
diagnosis, reported having had surgery to treat their cancer
(Table 3).
3.4. Changes in Health or Life Insurance Coverage due to
Cancer (Table 3). In 2010, cancer survivors less than 10 years
after diagnosis were significantly less likely to have health or
life insurance coverage denied due to their cancer diagnosis
compared to 1992 survey respondents who were less than 10
years after diagnosis, (𝑃 < 0.001).
3.5. Participation in Clinical Trials (Table 3). While the sam-
ple size for survivors (within <10 years of diagnosis in 1992
and 2010 survivors >10 years after diagnosis) who reported
participation in clinical trials was too small for accurate
interpretation, only 10.4% (95% CI = 8.5–12.8) of survivors in
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Table 2: Cancer diagnosis characteristics of survivors, 1992 and 2010 NHIS.
Characteristic 1992 cancer survivors 2010 cancer survivors P value
𝑁 % of total (95% confidence interval) 𝑁 % of total (95% confidence interval)
Total 1018 100.00 1718 100.00
How many types of cancer have you had
1 878 86.6 (83.9–88.9) 1542 89.4 (87.8–90.8) 0.05
2+ 140 13.4 (11.1–16.1) 176 10.6 (9.2–12.2)
Site or cancer type
Breast 217 20.6 (17.7–23.8) 393 22.9 (20.7–25.2)
†
Cervical 123 11.3 (9.2–13.7) 154 8.8 (7.4–10.4)
Colorectal 104 10.2 (7.9–12.9) 140 8.0 (6.8–9.5)
Hematologic malignancies ∗ ∗ 103 6.4 (5.2–7.9)
Lung and other respiratory system ∗ ∗ 57 3.6 (2.7–4.7)
Other female genital system 159 14.6 (12.3–17.3) 123 7.3 (5.9–9.1)
Prostate 78 8.9 (7.0–11.4) 231 13.1 (11.7–14.7)
Skin (melanoma) ∗ ∗ 142 9.5 (8.1–11.1)
Urinary system ∗ ∗ 81 5.2 (4.0–6.6)
Other 175 16.6 (14.3–19.2) 254 15.3 (13.5–17.2)
Age at diagnosis of most recent cancer (years)
0–29 154 15.2 (12.8–17.9) 221 12.9 (11.3–14.7)
0.002
30–44 235 23.9 (21.2–26.9) 318 18.2 (16.3–20.2)
45–54 142 14.5 (12.2–17.2) 311 17.9 (16.0–19.8)
55–64 178 18.6 (15.7–21.8) 395 22.8 (20.7–25.0)
65+ 288 27.8 (24.7–31.2) 458 28.3 (25.9–30.7)
Years since diagnosis of most recent cancer
<1 ∗ ∗ 89 5.8 (4.6–7.2)
<0.001
1 to <5 388 40.8 (37.4–44.4) 479 29.8 (27.4–32.3)
5 to <10 220 21.7 (18.9–24.8) 350 21.8 (19.6–24.3)
10 to <15 127 12.2 (10.2–14.6) 267 16.8 (14.9–18.9)
15 to <20 94 9.18 (7.3–11.5) 132 8.2 (6.9–9.7)
20+ 135 12.8 (10.6–15.3) 273 17.6 (15.5–19.9)
∗Suppressed if the denominator is <50 or the RSE is >30 percent.
Differences between 1992 and 2010 data were tested using chi-square tests.
†Statistical tests were not conducted where data were not reported consistently over time.
Subtotals presented do not equal actual totals because respondents with missing data for a particular characteristic are not included in distribution counts for
that characteristic.
2010 who were less than 10 years after diagnosis participated
in clinical trials.
3.6. Receipt of Counseling or Participation in Support Groups
(Table 3). Approximately 85% of survivors in 1992 and 2010
reportedly did not receive counseling or participate in a
support group, with the majority reporting they thought they
did not need this service. While more than twice as many
survivors in 2010, compared to those in 1992, reported that
they did not participate in counseling or a support group
because they “did not want it” (24.5% (95% CI = 21.3–28.0)
versus 11.6% (95% CI = 8.4–15.8)), more survivors in 2010,
particularly among those 10 years or more beyond diagnosis,
reported that they “did not know” counseling and support
group services were available to them (13.6% for <10 year
survivors (95% CI = 11.2–16.5) and 20.9% for >10 year
survivors (95% CI = 17.4–24.9), resp., versus 9.6% (95% CI
= 6.9–13.1)). Among 2010 survivors diagnosed within the
prior 10 years who reported that they did not participate in
counseling or support groups, 43% reported that they would
have been interested in receiving these services.
4. Discussion
According to our results, the proportion of cancer survivors
has increased over time, which is consistent with data from
the Behavioral Risk Factor Surveillance Survey (BRFSS)
[5] and NCI’s Surveillance, Epidemiology, and End Results
(SEER) [2, 3]. This growth is generally attributed to an aging
population and longer survival due to implementation of













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The increase from 1992 to 2010 in the proportion of sur-
vivors whoweremenwas not found in the general population
of respondents with no history of cancer.While exact reasons
for the gender difference among survivors are unknown, it is
possible that this is a result of the trend toward earlier diag-
nosis and possible over diagnosis of prostate cancer [13, 14].
Furthermore, the increasing proportion of survivors who are
Non-Hispanic Black may be attributed to findings showing a
continued increase in cancer survival rates of African Amer-
icans in the United States [2, 15]. However, changes in the
proportion of Non-Hispanic Black survivors in the US may
vary based on cancer type, stage of cancer, and other char-
acteristics [16]. The increases in the proportion of survivors
who were unmarried and with post-high-school education
are consistent with overall demographic trends in theUS [17].
The majority of cancer survivors in both 1992 and 2010
reported only having one type of cancer in their lifetime
and breast cancer was most frequently the primary cancer
type. Twenty-three percent of female cancer survivors in 2010
reported being breast cancer survivors, which is consistent
with SEER estimates reported in 2008 [2, 3]. However, these
2010 NHIS estimates are likely underreported given the
estimated increase in overall cancer survivors after 2008 [2].
While the increase in prostate cancers reported could be
the result of the rapid uptake of prostate cancer testing and
subsequent diagnosis among men, these findings may be
a result of the older age of the study sample. The sizable
proportion ofmelanoma skin cancers reported in 2010 can be
attributed to several factors, some of which include increases
in early detection and changes in behavior patterns related to
lifestyle choices, tanning, and sun exposure [18]. A decline in
other reported female gynecologic cancers was also found, in
part due to the decrease in the number of ovarian and uterine
cancers reported by survivors aged 30–44 years.
Differences in the age at diagnosis between 1992 and
2010 were also evident. While there was an overall decline in
proportion of cancer survivors under the age of 45 years at
the time of diagnosis in 2010, the most pronounced decrease
was among respondents aged 30 to 44 years. This reduction
was largely a result of a significant decrease in other female
gynecologic cancers in this age group (1992 NHIS = 26.0%;
2010 NHIS = 10.4%). Among those 45 years or older, an
increase in cancer survivors was noted in the 2010NHIS, with
the largest increase being among adults aged 55–64 years at
the time of diagnosis.This increase in 2010, compared to 1992,
was largely due to substantiallymore reported prostate (22.3%
versus 7.9%, resp.; data not shown) cancers diagnosed from
ages 55–64 years.
While there are several factors affecting long-term sur-
vival for individuals diagnosed with cancer, early detection
and advances in treatment and cancer related healthcare have
been associated with long-term cancer survival [3, 19], and
several of these advances have been reported since the 1992
survey. In accordance with the trend toward increased cancer
survival, the 2010 NHIS survey yielded an increased propor-
tion of survivors living 5 or more years after diagnosis, along
with an increase in those surviving 20 years or more. While
the proportion of cancer survivors living more than 5 years
continues to increase, these cancer survival improvements
maynot be equally shared by all due to differences in timing of
diagnosis, access to treatment and care, and other disparities
related to sociodemographic background [20].
According to the 1992 and 2010 NHIS surveys, use of sur-
gical treatment was reported more than any other treatment
by cancer survivors (Table 3).This findingwas expected given
that surgery is the oldest form of cancer treatment, is used for
curative intent, and provides a large benefit leading to cure for
breast cancer survivors [21] whomade up the largest group of
NHIS survivor respondents. Radiation was the second most
widely used treatment among 1992 and 2010 survivors who
were less than 10 years after diagnosis, which was expected
given that radiation after surgery (e.g., breast conservation) is
indicated for some cancers and can be helpful in reducing risk
of relapse or as a curative approach for some prostate cancers
[21, 22].
Clinical trials and research studies are needed for
advances in treatment and quality care for cancer survivors.
While the number of survivors in 1992 reporting involvement
in clinical trials and research studies was too small for
interpretation, previous researches looking at clinical trial
and research study involvement in 1992 indicate that only
5% of survivors participated in such activities [4]. Com-
pared with this previous finding, current analyses suggest
a potential increase in these numbers and prevalence from
1992 to 2010. This may reflect broader public awareness
about the importance of research participation and more
effective [23] media campaigns for clinical trials [24]. While
rates of participation in research may be increasing, overall
participation is still low (9%) and maybe even lower for
certain racial/ethnic groupswho, historically, have beenmore
reticent to participate in experimental research [20].
Our finding that fewer cancer survivors in 2010 reported
being denied health or life insurance coverage is encourag-
ing. Cancer survivors have traditionally reported difficulties
getting approval for health and life insurance coverage due
to preexisting condition clauses [4, 25]. While improvements
in insurance coverage for working cancer survivors have
been achieved since the implementation of the 1996 Health
Insurance Portability and Accountability Act (HIPAA), a
minority of survivors may still experience difficulties in
achieving insurance coverage due to employment status, age,
health status, income, high premium costs, and a plethora of
other concerns [25].
No significant changes from 1992 to 2010 were reported
regarding participation in counseling or support groups
among cancer survivors. Only 14% of cancer survivors in
both 1992 and 2010 reported participation in counseling or
support groups. But, consistent with other reports of low
participation in these services [5, 26], this lack of change over
time is, nevertheless, surprising given the broader availability
of and access to insurance coverage for psychosocial care
in the past decade. These results are also concerning given
that cancer survivors often experience psychosocial, neu-
rocognitive, vocational, financial, and other related concerns
across the cancer continuum [27–30]. Among 1992 and 2010
cancer survivors who did not report receiving counseling
or supportive services, the majority continue to state that
they “did not think they needed” these services, which may
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be appropriate given that many survivors report resilience
after cancer [30, 31]. The moderately high numbers of cancer
survivors in both study years reporting that they “did not
know” these services were available are consistent with pre-
vious research reporting that primary care providers do not
routinely or effectively communicate with cancer survivors
about quality of life, psychosocial concerns, and supportive
care [32]. It is, however, surprising that there is still a high
proportion of survivors unaware of psychosocial services
given recent prominent publications on these services [32,
33], the growing number of cancer outreach groups, and the
increasing amount of information available on the Internet.
One possible explanation for the static rates of participation
in professional counseling and support groups may be the
availability of support in online formats [34]. Participation
in counseling or supportive service might also vary based
on demographic factors (e.g., age, race/ethnicity, income, and
education), health characteristics (e.g., years since diagnosis,
stage of cancer, and projected survival), and the amount of
support a cancer survivor might receive from their family,
friends, and members of their community [34, 35]. Addi-
tionally, psychosocial services may not be readily available to
cancer survivors who were not treated at large cancer centers
or hospitals where psychosocial care is more likely integrated
into the treatment and followup care process.
4.1. Strengths, Limitations, and Future Considerations. Our
study makes an important contribution to the current lit-
erature by comparing estimates of healthcare characteristics
for cancer survivors responding to the NHIS survey before
and after the release of several notable reports [4, 8], which
illustrated gaps and needs in cancer care and survivorship.
The results of our study, which were based on data from a
large sample of US adults, are useful in assessing changes
in cancer characteristics, healthcare provision, involvement
in clinical trials and supportive services (e.g., counseling),
and changes in sociodemographic characteristics of cancer
survivors over time. While our findings show improvements
in insurance coverage, gaps in psychosocial care illuminated
in the 2005 IOM publication [8] are still evident. Our
use of population-based self-report data also complements
other data sources (e.g., SEER) by allowing examination of
important aspects of survivorship not captured by registries.
Limitations to our study include possible recall and
differential misclassification biases, as well as the effects of
differences in how respondents interpreted survey questions.
Respondents who were very ill may have been less likely to
participate in the survey. Further, these results are not gen-
eralizable to institutionalized individuals because they are
not included in the NHIS sample frame. The NHIS data
are adjusted to the civilian noninstitutionalized population
through poststratification and weighting. While the sample
of US adults surveyed was large, the smaller size of the
subgroup of cancer survivors limits statistical power. Another
limitation is possible self-reported misclassification of cancer
type that would increase or reduce reported rates [36].
Additionally, changes made to survey questions over time
limited comparability among questions, and small numbers
precluded interpretation of estimates for some questions.
Lastly, given the large number of statistical comparisons,
some findings may be spurious.
The characteristics of cancer survivors are changing over
time, and understanding these changes is a first step in
meeting the needs of this growing population. Fortunately,
survivors are living longer after diagnosis, and the negative
impact of cancer on insurance coverage has declined. How-
ever, opportunities exist to improve supportive services to
survivors and to increase participation in clinical trials. We
suggest that future studies of cancer survivors continue to
examine the impact that demographic, as well as cancer and
healthcare, characteristics play on survivorship outcomes,
especially in the context of anticipated changes brought on
healthcare legislation that are likely to affect theways inwhich
service delivery, insurance coverage, and overall healthcare
are employed over time [37]. Additional research should
also examine access to cancer clinical trials, counseling, and
supportive services, as well as factors affecting participation
in these activities and ways of improving awareness and
utilization of these services.
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